Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;25(3):243-262.
doi: 10.2174/0115680266299112240514103048.

Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment

Shahram Taeb  1 , Davoud Rostamzadeh  2 , Seyed Mohammad Amini  3 , Mohammad Rahmati  4 , Mostafa Golshekan  5 , Mahmoud Abedinzade  6 , Elham Ahmadi  2 , Singh Neha  2 , Masoud Najafi  7
Affiliations
Review

Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment

Shahram Taeb et al. Curr Top Med Chem. 2025.

Abstract

In recent years, mesenchymal stem cells (MSCs) have emerged as promising anti-- cancer mediators with the potential to treat several cancers. MSCs have been modified to produce anti-proliferative, pro-apoptotic, and anti-angiogenic molecules that could be effective against a variety of malignancies. Additionally, customizing MSCs with cytokines that stimulate pro-tumorigenic immunity or using them as vehicles for traditional chemical molecules with anti-cancer characteristics. Even though the specific function of MSCs in tumors is still challenged, promising outcomes from preclinical investigations of MSC-based gene therapy for a variety of cancers inspire the beginning of clinical trials. In addition, the tumor microenvironment (TME) could have a substantial influence on normal tissue stem cells, which can affect the treatment outcomes. To overcome the complications of TME in cancer development, MSCs could provide some signs of hope for converting TME into unequivocal therapeutic tools. Hence, this review focuses on engineered MSCs (En-MSCs) as a promising approach to overcoming the complications of TME.

Keywords: Angiogenesis.; Cancer; Cytokines; Engineered MSCs (En-MSCs); Mesenchymal stem cells (MSCs); Stem cells; Tumor microenvironment (TME).

PubMed Disclaimer

References

    1. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249 - DOI - PubMed
    1. Siegel R.L.; Miller K.D.; Fuchs H.E.; Jemal A.; Cancer statistics, 2021. CA Cancer J Clin 2021,71(1),7-33 - DOI - PubMed
    1. Merlo L.M.F.; Pepper J.W.; Reid B.J.; Maley C.C.; Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006,6(12),924-935 - DOI - PubMed
    1. Xiao Y.; Yu D.; Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 2021,221,107753 - DOI - PubMed
    1. Nisar S.; Yousuf P.; Masoodi T.; Wani N.A.; Hashem S.; Singh M.; Sageena G.; Mishra D.; Kumar R.; Haris M.; Bhat A.A.; Macha M.A.; Chemokine-cytokine networks in the head and neck tumor microenvironment. Int J Mol Sci 2021,22(9),4584 - DOI - PubMed

MeSH terms

Substances